Published in Mol Pharmacol on November 07, 2008
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol (2010) 1.76
Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med Chem (2009) 1.49
EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. PLoS One (2015) 1.46
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res (2009) 1.37
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A (2010) 1.25
Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2010) 1.06
A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol (2013) 1.03
Regulation of Cisplatin cytotoxicity by cu influx transporters. Met Based Drugs (2011) 1.00
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol (2010) 1.00
An all-atom model of the structure of human copper transporter 1. Cell Biochem Biophys (2012) 0.95
The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Mol Pharmacol (2010) 0.93
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol (2014) 0.91
The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. J Inorg Biochem (2012) 0.91
Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear Res (2011) 0.90
Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat (2012) 0.90
The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochem Pharmacol (2010) 0.89
Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics (2014) 0.88
NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget (2016) 0.87
Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1. Oncoscience (2014) 0.86
Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol (2014) 0.85
The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer (2015) 0.85
Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genomics Proteomics Bioinformatics (2014) 0.85
Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano (2013) 0.84
Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. J Ovarian Res (2013) 0.84
Roles of Atox1 and p53 in the trafficking of copper-64 to tumor cell nuclei: implications for cancer therapy. J Biol Inorg Chem (2014) 0.83
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury. HPB (Oxford) (2012) 0.82
The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B. Metallomics (2013) 0.82
Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo) (2012) 0.81
Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother Pharmacol (2011) 0.80
ATP7B detoxifies silver in ciliated airway epithelial cells. Toxicol Appl Pharmacol (2009) 0.80
Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. Mol Pharmacol (2012) 0.80
Uptake carriers and oncology drug safety. Drug Metab Dispos (2013) 0.79
Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Biochem Pharmacol (2014) 0.79
Different gap junction-propagated effects on cisplatin transfer result in opposite responses to cisplatin in normal cells versus tumor cells. Sci Rep (2015) 0.79
A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment. Int J Hyperthermia (2013) 0.79
Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306. Mol Pharm (2014) 0.78
Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet (2012) 0.78
Role of copper transporters in platinum resistance. World J Clin Oncol (2016) 0.78
Copper transporter 2 content is lower in liver and heart of copper-deficient rats. Int J Mol Sci (2010) 0.77
The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2). Metallomics (2015) 0.76
β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. Sci Rep (2016) 0.76
Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics (2016) 0.76
The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets. Oncotarget (2016) 0.75
Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-DNA damage. Br J Pharmacol (2016) 0.75
Role of transporters in the distribution of platinum-based drugs. Front Pharmacol (2015) 0.75
Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells. J Biol Inorg Chem (2017) 0.75
In Vitro and in vivo Evaluation of Electrochemotherapy with trans-platinum Analogue trans-[PtCl2(3-Hmpy)2]. Radiol Oncol (2017) 0.75
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (1991) 9.39
Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol (2008) 4.03
Molecular characterization of a copper transport protein in S. cerevisiae: an unexpected role for copper in iron transport. Cell (1994) 3.88
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A (2002) 3.28
The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. J Biol Chem (1994) 2.57
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis. EMBO J (1996) 1.93
Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem (2002) 1.91
The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci U S A (2001) 1.90
Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J Biol Chem (2002) 1.89
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther (2004) 1.82
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol (2006) 1.75
Projection structure of the human copper transporter CTR1 at 6-A resolution reveals a compact trimer with a novel channel-like architecture. Proc Natl Acad Sci U S A (2006) 1.66
Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene (2000) 1.64
The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol (2002) 1.62
Essential role for Atox1 in the copper-mediated intracellular trafficking of the Menkes ATPase. Proc Natl Acad Sci U S A (2003) 1.62
The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2004) 1.53
The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res (2006) 1.51
The metallochaperone Atox1 plays a critical role in perinatal copper homeostasis. Proc Natl Acad Sci U S A (2001) 1.45
Eukaryotic CTR copper uptake transporters require two faces of the third transmembrane domain for helix packing, oligomerization, and function. J Biol Chem (2004) 1.44
Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J Biol Chem (2007) 1.27
Copper homeostasis in eukaryotes: teetering on a tightrope. Biochim Biophys Acta (2006) 1.26
Maintaining copper homeostasis: regulation of copper-trafficking proteins in response to copper deficiency or overload. J Nutr Biochem (2004) 1.24
A structural perspective on copper uptake in eukaryotes. Biometals (2007) 1.20
Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem (2006) 1.12
Copper deficiency. Curr Opin Gastroenterol (2007) 1.10
Characterization of the hCTR1 gene: genomic organization, functional expression, and identification of a highly homologous processed gene. Gene (2000) 1.05
Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis. Biochem Pharmacol (2006) 0.88
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res (2002) 1.98
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther (2005) 1.89
Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res (2003) 1.79
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol (2006) 1.75
The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol (2002) 1.62
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol (2005) 1.61
Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells. ACS Nano (2011) 1.61
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2004) 1.53
The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res (2006) 1.51
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res (2004) 1.49
Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res (2004) 1.44
Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol (2004) 1.41
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res (2009) 1.37
Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res (2005) 1.30
Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol (2007) 1.30
DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res (2004) 1.24
Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res (2004) 1.23
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res (2009) 1.22
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A (2007) 1.22
Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol Pharmacol (2003) 1.20
Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. J Inorg Biochem (2008) 1.16
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res (2004) 1.14
Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem (2006) 1.12
In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles. Nat Commun (2013) 1.11
Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res (2006) 1.10
The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol (2003) 1.10
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol (2002) 1.10
Intra-arterial chemotherapy for head and neck cancer: is there a verdict? Cancer (2010) 1.10
Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia (2012) 1.09
DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther (2006) 1.09
Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2010) 1.06
Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol (2003) 1.06
The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem (2004) 1.03
Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (2006) 1.03
Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. Biochem Pharmacol (2012) 1.02
Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res Treat (2006) 1.02
Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol (2009) 1.02
Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol (2009) 1.01
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res (2013) 1.00
Regulation of Cisplatin cytotoxicity by cu influx transporters. Met Based Drugs (2011) 1.00
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol (2010) 1.00
Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. Int J Nanomedicine (2010) 1.00
DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res (2006) 0.99
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol (2009) 0.99
Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol (2005) 0.99
Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2006) 0.98
Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol (2005) 0.98
Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther (2009) 0.97
An all-atom model of the structure of human copper transporter 1. Cell Biochem Biophys (2012) 0.95
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol (2007) 0.95
Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4. PLoS One (2013) 0.94
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol (2004) 0.93
CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm (2010) 0.93
The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Mol Pharmacol (2010) 0.93
A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther (2011) 0.92
The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. J Inorg Biochem (2012) 0.91
The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochem Pharmacol (2010) 0.89
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol (2005) 0.89
Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics (2014) 0.88
Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Mol Pharmacol (2012) 0.88
Acidic hydrolysis of N-Ethoxybenzylimidazoles (NEBIs): potential applications as pH-sensitive linkers for drug delivery. Bioconjug Chem (2007) 0.88
Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum. Small (2011) 0.87
Characterization of a clinical polymer-drug conjugate using multiscale modeling. Biopolymers (2010) 0.87
Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. BMC Cancer (2011) 0.84
Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol (2006) 0.83
Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae. Mol Pharmacol (2008) 0.83
The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B. Metallomics (2013) 0.82
Dynamics of soft nanomaterials captured by transmission electron microscopy in liquid water. J Am Chem Soc (2014) 0.81
Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother Pharmacol (2011) 0.80
Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. Mol Pharmacol (2012) 0.80
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol Oncol (2009) 0.79
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.79
Aggregation properties of a polymeric anticancer therapeutic: a coarse-grained modeling study. J Chem Inf Model (2011) 0.79
NMR and mutagenesis of human copper transporter 1 (hCtr1) show that Cys-189 is required for correct folding and dimerization. Biochim Biophys Acta (2007) 0.78
Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine. Mol Pharmacol (2002) 0.77
Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics (2016) 0.76
The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2). Metallomics (2015) 0.76
Cellular Delivery of Nanoparticles Revealed with Combined Optical and Isotopic Nanoscopy. ACS Nano (2016) 0.75
Coarse-grained modeling study of nonpeptide RGD ligand density and PEG molecular weight on the conformation of poly(γ-glutamyl-glutamate) paclitaxel conjugates. J Mol Model (2011) 0.75
Integrin αV control of Cu homeostasis and cisplatin sensitivity. Cell Cycle (2014) 0.75
Effects of solution concentration on the physicochemical properties of a polymeric anticancer therapeutic. Mol Pharm (2011) 0.75